Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal Phase 3 IMforte trial Zepzelca and atezolizumab ...
A Mount Sinai study examined how sex-based pelvic anatomical differences affect S2 alar-iliac (S2AI) screw placement and rod ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback